George Medicines
About
George Medicines is a late-stage biopharmaceutical company dedicated to developing innovative single-pill combination therapies for cardiometabolic diseases and other non-communicable conditions. As a venture-backed spin-out from The George Institute for Global Health, the company aims to improve the lives of individuals affected by hypertension, diabetes, and similar disorders. Their unique approach combines existing treatments into novel multi-mechanism combinations, which streamlines the development process and enhances the likelihood of success. The company has a proprietary pipeline that includes key products like WIDAPLIK, the first FDA-approved triple combination medication for hypertension, and GMRx2, which offers multiple dosing options for hypertension treatment. George Medicines collaborates with global pharmaceutical companies and clinical organizations to advance its pipeline, ensuring that treatments are both affordable and accessible, especially in developing countries where non-communicable diseases pose a significant challenge.